Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland. Show more
Location: 910 Clopper Road, Gaithersburg, MD, 20878, United States | Website: https://altimmune.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
335.8M
52 Wk Range
$2.90 - $11.16
Previous Close
$4.40
Open
$4.32
Volume
4,159,229
Day Range
$4.10 - $4.35
Enterprise Value
165.6M
Cash
149.8M
Avg Qtr Burn
-20.08M
Insider Ownership
0.76%
Institutional Own.
47.85%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Pemvidutide (ALT-801) (GLP-1R/GCGR) Details Metabolic dysfunction-associated steatohepatitis (MASH) | Phase 2b Data readout | |
Pemvidutide (ALT-801) (GLP-1R/GCGR) Details Alcohol Use Disorder | Phase 2 Data readout | |
Pemvidutide (ALT-801) (GLP-1R/GCGR) Details Alcohol-Associated Liver Disease | Phase 2 Data readout | |
Phase 2 Update | ||
NasoShield (Vaccine) Details Anthrax, Bacterial infection | Failed Discontinued | |
T-COVID Details COVID-19 | Failed Discontinued | |
AdCOVID Details COVID-19 | Failed Discontinued | |
NasoVAX Details Influenza | Failed Discontinued | |
HepTCell Details Chronic hepatitis B | Failed Discontinued |